LATEST NEWS Press Releases & News Alerts MAR 16, 2026 Lucid Acts as Sole Book-Runner for Swarmer’s $17.3M Initial Public Offering MAR 13, 2026 Lucid Acts as Lead Book-Runner for Oxford Lane Capital Corp.'s $60.0M Term Preferred Stock Offering FEB 27, 2026 Lucid Acts as Co-Manager for Palvella Therapeutics’s $230.0M Upsized Follow-on Offering FEB 18, 2026 Lucid Capital Markets Acts as Financial Advisor to Sensei Biotherapeutics in its Acquisition of Faeth Therapeutics FEB 10, 2026 Lucid Acts as a Joint Bookrunner for Gladstone Investment Corporation's $100.0M Public Notes Offering FEB 3, 2026 Lucid Acts as Joint Placement Agent for Adlai Nortye’s $140.0M Private Placement FEB 2, 2026 Lucid Acts as a Joint Bookrunner for CION Investment Corporation's $125.0M Public Notes Offering JAN 30, 2026 Lucid Acts as Lead Book-Runner for Saratoga Investment Corp.'s $100.0M Public Notes Offering JAN 28, 2026 Lucid Acts as Lead Book-Runner for United Acquisition Corp. I's $100.0M Initial Public Offering JAN 27, 2026 Lucid Acts as a Joint Book-Runner for Runway Growth Finance Corp.'s $100.0M Public Notes Offering JAN 16, 2026 Lucid Acts as Lead Book-Runner for Mount Logan Capital Inc's $40.0M Public Notes Offering JAN 13, 2026 Lucid Acts as a Co-Manager for Rithm Capital Corp's $250m Preferred Stock Offering JAN 9, 2026 Lucid Acts as Sole Book-Runner for flyExclusive’s $15.0M Public Offering JAN 8, 2026 Lucid Acts as Sole Book-Runner for Genelux Corporation’s $20.0M Follow-on Offering NOV 10, 2025 Lucid Acts as Financial Advisor to the Board of Directors of Galecto in its Acquisition of Damora Therapeutics NOV 5, 2025 Lucid Acts as a Co-Manager for Ramaco Resources’ $300m Convertible Notes Offering. OCT 27, 2025 Lucid Acts as Sole Book-Runner for Coya Therapeutics’s $23.0M Upsized Follow-on Offering OCT 23, 2025 Lucid Capital Markets acted as the Lead Bookrunner for Carlyle Credit Income Fund's $30.0M Term Preferred Stock Offering. SEP 30, 2025 Lucid Capital Markets acted as a Co-Manager on Carlyle Secured Lending Inc's $300m Notes Offering SEP 18, 2025 Lucid Acts as Co-Manager for Rithm Capital Corp's $190M Preferred Stock Offering SEP 11, 2025 Lucid Acts as Sole Book-Runner for Actuate Therapeutics’s $17.3M Follow-on Offering SEP 4, 2025 Lucid Acts as Lead Bookrunner for Great Elm Capital Corp's $50m Notes Offering AUG 20, 2025 Lucid Acts as Financial Advisor to Mural Oncology in its Acquisition by Xoma JUL 31, 2025 Lucid Acts as Lead Bookrunner for Oxford Square Capital Corp's $65m Notes Offering JUL 24, 2025 Lucid Acts as Co-Manager for NETSTREIT Corp's $191m Follow-on Offering JUL 23, 2025 Lucid Acts as Lead Bookrunner for Ramaco Resources' $57m Notes Offering JUL 16, 2025 Lucid Acts as Lead Bookrunner for OFS Capital Corporation's $60m Notes Offering JUL 14, 2025 Lucid Provides Fairness Opinion in Connection with Sonnet’s Reverse Merger with HyperLiquid JUL 8, 2025 Lucid Acts as Joint Bookrunner for Sound Point Meridian Capital Inc's $50m Preferred Stock Offering JUN 23, 2025 Lucid Provides Fairness Opinion in Connection with Carisma’s Reverse Merger with OrthoCellix JUN 16, 2025 Lucid Acts as Financial Advisor to GlycoMimetics in its Merger with Crescent Biopharma MAY 16, 2025 Lucid acts as Joint Bookrunner for Medallion Bank's $75m Perpetual Preferred Stock Offering FEB 26, 2025 Lucid Acts as Co-Manager for Rithm Property Trust Inc's $50m Preferred Stock Offering FEB 19, 2025 Lucid Acts as Lead Bookrunner for Oxford Lane Capital Corp's $165m Notes Offering FEB 7, 2025 Lucid Acts as Sole Bookrunner for Nuvectis Pharma’s $15.5M Follow-on Offering DEC 31, 2024 Lucid Provides Fairness Opinion in Connection with Galera’s Acquisition of Nova Pharmaceuticals DEC 13, 2024 Lucid Acts as Lead Bookrunner for Pearl Diver Credit Corp's $30m Preferred Stock Offering DEC 4, 2024 Lucid Acts as Lead Bookrunner for Eagle Point Credit Company $100 Million Notes Offering NOV 21, 2024 Lucid Acts as Lead Bookrunner for Ramaco Resources $50 Million Senior Notes Offering AUG 21, 2024 Lucid Established Healthcare Equity Research Group with Addition of Christopher Liu and Dev Prasad JUL 23, 2024 Lucid Establishes Specialty Finance Equity Research Group with the Hiring of Erik Zwick JUL 19, 2024 Lucid Establishes REIT Equity Research Group with the Hiring of Craig Kucera JUL 09, 2024 Lucid is named lead placement agent on Saratoga Investment Corporation’s $300 million ATM program JUN 26, 2024 Lucid Acts as Lead Left Bookrunner on $100M note offering of Oxford Lane Capital Corp JUN 18, 2024 Lucid acts as Lead Bookrunner on the $69 million IPO of Flagship Acquisition Corp. JUN 07, 2024 Lucid is named sole bookrunner of Rising Dragon Acquisition Corp.’s $50 million IPO MAY 10, 2024 Lucid is named sole bookrunner of YHN Acquisition Corp.’s $60 million IPO APR 03, 2024 Lucid is Named as Financial Advisor to ARCA Biopharma in a Reverse Merger Transaction with Oruka Therapeutics APR 03, 2024 Lucid is Named as Financial Advisor to Kintara Therapeutics in a Reverse Merger Transaction with TuHura Biosciences For press and news enquiries, please contact our team. PRESS ENQUIRIES
